Mirati Therapeutics Inc MRTX:NASDAQ

RT Quote | NASDAQ | USD
Last | 07/05/22 EDT
71.96quote price arrow up+0.78 (+1.10%)
Volume
1,120,382
52 week range
32.96 - 195.99
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close71.96
  • 52 Week High195.99
  • 52 Week High Date10/25/21
  • 52 Week Low32.96
  • 52 Week Low Date05/27/22

Key Stats

  • Market Cap3.996B
  • Shares Out55.53M
  • 10 Day Average Volume1.30M
  • Dividend-
  • Dividend Yield-
  • Beta1.10
  • YTD % Change-50.94

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close71.96
  • 52 Week High195.99
  • 52 Week High Date10/25/21
  • 52 Week Low32.96
  • 52 Week Low Date05/27/22
  • Market Cap3.996B
  • Shares Out55.53M
  • 10 Day Average Volume1.30M
  • Dividend-
  • Dividend Yield-
  • Beta1.10
  • YTD % Change-50.94

RATIOS/PROFITABILITY

  • EPS (TTM)-11.90
  • P/E (TTM)-6.05
  • Fwd P/E (NTM)-4.99
  • EBITDA (TTM)-622.862M
  • ROE (TTM)-50.58%
  • Revenue (TTM)72.80M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-871.54%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date08/03/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Mirati Therapeutics Inc

Profile

MORE
Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to...
Faheem Hasnain
Lead Independent Chairman of the Board
David Meek
Chief Executive Officer, Director
Charles Baum M.D., Ph.D.
President, Founder, Director, Head of Research and Development
Laurie Stelzer CPA
Chief Financial Officer
Address
3545 Cray Court
San Diego, CA
92121
United States

Top Peers

SYMBOLLASTCHG%CHG
AUPH
Aurinia Pharmaceuticals Inc
12.37+0.98+8.60%
BLU
BELLUS Health Inc
10.04+0.74+7.96%
ABUS
Arbutus Biopharma Corp
2.88+0.08+2.86%
TH
Target Hospitality Corp
5.21-0.41-7.30%
MBX